Antithrombin III utilization in a large teaching hospital

P and T

Volumn 38, Issue 12, 2013, Pages

  Salas, Cristina M ^a   Miyares, Marta A ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Antithrombin; Atryn; Thrombate III; Veno occlusive disease

Indexed keywords

ANTITHROMBIN III;

ADOLESCENT; ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; CHILD; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG COST; DRUG INDICATION; DRUG UTILIZATION; FEMALE; HEART SURGERY; HUMAN; INFANT; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MEDICAL RECORD REVIEW; NEPHRITIS; PHARMACY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; TEACHING HOSPITAL; TREATMENT DURATION; VEIN OCCLUSION;

EID: 84890415822     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin defciency. Thromb Haemost 2009;101(5):806-812.
2. Maclean PS, Campbell Tait R. Hereditary and acquired antithrom-bin defciency: Epidemiology, pathogenesis, and treatment options. Drugs 2007;67(10):1429-1440.
3. Odegård OR, Abildgaard U, Antithrombin III: Critical review of assay methods. Signifcance of variations in health and disease. Haemostasis 1978;7(2-3):127.
4. Meade TW, Dyer S, Howarth DJ, et al. Antithrombin III and pro-coagulant activity: Sex differences and effects of the menopause. Br J Haematol 1990;74(1):77.
5. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin III defciency subtypes in 4000 healthy blood donors. Thromb Haemost 1992;65:839.
6. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin defciency in the healthy population. Br J Haematol 1994;87(1):106.
7. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: Results of the Spanish Multi-centric Study on Thrombophilia (EMET Study). Thromb Haemost 1997;77(3):444.
8. Konkle, BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrom-bin defciency undergoing surgical procedures. Transfusion 2003;43(3):390-394.
9. Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired defciency of antithrombin. The Antithrombin III Study Group. Am J Med 1989;87(3B):53S-60S.
10. Menache D, O'Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical effcacy of antithrombin III (human) in patients with hereditary antithrombin III defciency. Cooperative Study Group. Blood 1990;75(1):33-39.
11. Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired defciency states. Transfusion 1998;38(5):481-498.
12. Thrombate III, prescribing information. Triangle Park, N.C.: Grifols/Talecris; 2009.
13. A Tryn, prescribing information. Deerfeld, Ill.: Ovation Pharmaceuticals, Inc.; 2009.
14. Senzolo G, Germani G, Cholangitas E, et al. Veno-occlusive disease: Update on clinical management. World J Gastroenterol 2007;13(29):3918-3924.
15. Pegram AA, Kennedy LD. Prevention and treatment of veno-occlusive disease. Ann Pharmacother 2001;35(7-8):935-942.
16. Niebler RA, Christensen M, Berens R, et al. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs 2011;35(11):1024-1028.
17. Agati S, Ciccarello G, Salvo D, et al. Use of a novel anticoagulation strategy during ECMO in a pediatric population: Single-center experience. ASAIO J 2006;52(5):513-516.
18. du Cheyron D, Bouchet B, Bruel C, et al. Antithrombin supplementation for anticoagulation during continuous hemofltration in critically ill patients with septic shock: A case-control study. Crit Care 2006;10(2):R45.
19. Brunner R, Leiss W, Madl C, et al. Single-dose application of antithrombin as a potential alternative anticoagulant during continuous renal replacement therapy in critically ill patients with advanced liver cirrhosis: A retrospective data analysis. Anesth Analg 2013;116(3):527-532.
20. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000;70(3):873-877.
21. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. Ann Intern Med 1998;128(12 Part 1):975-981.
22. Park SH, Lee MH, Lee H, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29(2):137-143.
23. Lakshminarayanan S, Sahdev I, Goyal M, et al. Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution. Pediatr Transplant 2010;14(5):618-621.
24. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000;64(1):32-38.
25. Or R, Nagler A, Shpilberg O, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996;15;61(7):1067-1071.
26. Batsis I, Yannaki E, Kaloyannidis P, et al. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation. Thromb Res 2006;118(5):611-618.
27. Simon M, Hahn T, Ford LA, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible benefcial use of low molecular weight heparin. Bone Marrow Transplant 2001;27(6):627-633.
28. Song JS, Seo JJ, Moon HN, et al. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci 2006;21(5):897-903.
29. Forrest DL, Thompson K, Dorcas VG, et al. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study. Bone Marrow Transplant 2003;31(12):1143-1149.
30. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992;79(11):2834-2840.
31. Marsa-Vila L, Gorin NC, Laporte J P, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur Haematol 1991;47(5):346-354.
32. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: Impact of pre-emptive antithrombin III replacement and combined antithrombin III/ defbrotide therapy. Haematologica 2006;91(6):795-800.
33. Morris JD, Harris RE, Hashmi R, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997;20(10):871-878.
34. Mertens R, Brost H, Granzen B, Nowak-Gottl U. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr 1999(158 Suppl 3):S154-S158.
35. Patton DF, Harper JL, Wooldridge TN, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997;20(10):871-878.
36. Shin-Nakai N, Ishida H, Yoshihara T, et al. Control hepatic veno-occlusive disease with an antithrombin-III concentrate-based therapy. Pediatr Int 2006;48(1):85-87.
37. Peres E, Kintzel P, Dansey R, et al. Early intervention with anti-thrombin III therapy to prevent hepatic veno-occlusive disease. Blood Coagul Fibrinolysis 2008;19(3):203-207.